The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque ...

The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

Pain on the outer side of your foot can range from annoying to debilitating. When the stabbing, burning, or aching is severe, it can limit your ability to stand, walk, exercise, work, or engage in ...

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study.

Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced today that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable ...

Psoriasis is a disease that causes red patches of skin with silvery scales. foot problems According to the National Psoriasis Foundation, 30% of individuals with psoriasis develop PsA. PsA causes ...

There could be lots of reasons your feet hurt or your toes ache, yet muscle cramps tend to be a common culprit. You know that strange thing when your toes start twitching and involuntarily ...

“They leave it out of the discussion,” he says. “For patients who have the most common type of psoriasis, plaque psoriasis, there is not a clear, established relationship with thyroid ...

A warm, hot, or burning feeling in the feet is not always serious, but it can be a sign of a fungal infection, diabetes, or other conditions. Share on Pinterest Fiordaliso/Getty Images ...

Phase 3 trial results released by Protagonist Therapeutics has revealed that icotrokinra, an oral IL-23 receptor inhibitor, achieved clear or nearly clear skin in 66% of patients with ...

Findings also showed that among the small subset of patients with hand and/or foot psoriasis ... treatment paradigm in moderate-to-severe plaque psoriasis, by offering a combination of skin ...

Psoriasis is a chronic inflammatory disorder for which phosphodiesterase-4 (PDE4) inhibitors have emerged as promising therapeutic agents due to an ability to regulate inflammatory signaling pathways.